retatrutide update 🚨 BREAKING: Shows “Bariatric-Level” Weight Loss in Phase 3 Trial New Phase 3 TRIUMPH-1 data show retatrutide may deliver weight-loss outcomes approaching those seen with bariatric surgery—marking one of the most Retatrutide Phase 3: 60% Achieved
Description
To qualify, a patient's provider must submit a prior authorization request showing that the patient is being prescribed a GLP-1 for weight loss
Adverse Reactions Adverse reactions commonly associated with Lantus include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain
Taqueti and Di Carli, 2018)
The trial also demonstrated a favorable tolerability profile for the 7.2mg dose
Rapid weight loss loss can outpace the skins ability to tighten, especially after years of stretching, pregnancy, or age-related collagen changes
The literature study demonstrates the utilization of botanical and plant-derived treatments for the management of type 2 diabetes mellitus
